Literature DB >> 29674438

(Iso-)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer.

Maximilian Boesch1,2,3,4, Daniel Reimer5, Sieghart Sopper2,4, Dominik Wolf2,6, Alain G Zeimet7.   

Abstract

Entities:  

Keywords:  Cancer stem cell; Guanine nucleotide exchange factor; Protein isoform; Transcript variant; Vav3

Mesh：

Substances：

Year:  2018        PMID： 29674438      PMCID： PMC6058338          DOI： 10.1634/theoncologist.2017-0683

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis.

Authors:  Sonja G Hunter; Guanglei Zhuang; Dana Brantley-Sieders; Wojciech Swat; Christopher W Cowan; Jin Chen
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

2.  Differential Gene Expression of the Proto-oncogene VAV3 and the Transcript Variant VAV3.1 in Oral Squamous Cell Carcinoma.

Authors:  Thomas Trenkle; Samer G Hakim; Hans-Christian Jacobsen; Peter Sieg
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

3.  Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins.

Authors:  N Movilla; X R Bustelo
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

4.  Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.

Authors:  Leah S Lyons; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2005-12-29

5.  Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.

Authors:  Kyung Hee Chang; Abel Sanchez-Aguilera; Shuhong Shen; Amitava Sengupta; Malav N Madhu; Ashley M Ficker; Susan K Dunn; Ashley M Kuenzi; Jorden L Arnett; Rebecca A Santho; Xabier Agirre; John P Perentesis; Michael W Deininger; Yi Zheng; Xose R Bustelo; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

6.  Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; David Vaught; Tanner Freeman; Yoonha Hwang; Donna Hicks; Jin Chen
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

Review 7.  Vav proteins, masters of the world of cytoskeleton organization.

Authors:  Idit Hornstein; Andres Alcover; Shulamit Katzav
Journal:  Cell Signal       Date:  2004-01       Impact factor: 4.315

8.  Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Authors:  Daniel Reimer; Maximilian Boesch; Dominik Wolf; Christian Marth; Sieghart Sopper; Jiri Hatina; Peter Altevogt; Walther Parson; Hubert Hackl; Alain G Zeimet
Journal:  Int J Cancer       Date:  2017-12-14       Impact factor: 7.396

9.  The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops.

Authors:  Mauricio Menacho-Márquez; Ramón García-Escudero; Virginia Ojeda; Antonio Abad; Pilar Delgado; Clotilde Costa; Sergio Ruiz; Balbino Alarcón; Jesús M Paramio; Xosé R Bustelo
Journal:  PLoS Biol       Date:  2013-07-23       Impact factor: 8.029

10.  The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Authors:  Maximilian Boesch; Alain G Zeimet; Daniel Reimer; Stefan Schmidt; Guenther Gastl; Walther Parson; Franziska Spoeck; Jiri Hatina; Dominik Wolf; Sieghart Sopper
Journal:  Oncotarget       Date:  2014-08-30
  10 in total
  1 in total

1.  Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Authors:  Maximilian Boesch; Sieghart Sopper; Christian Marth; Heidi Fiegl; Annemarie Wiedemair; Julia Rössler; Jiri Hatina; Dominik Wolf; Daniel Reimer; Alain G Zeimet
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-06       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.